Categories
Change Password!
Reset Password!
Serum calprotectin is a useful biomarker for tracking
disease activity; detect inflammatory disease in patients complaining of
arthralgia, neutrophil initiation (more effective as compared to CRP) and,
severity of disease and prognosis in RA and axSpA.
A recent study published in May of ‘Arthritis Research & Therapy’ confirmed
about the relationship of serum calprotectin levels with disease
activity in both rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA),
except in psoriatic arthritis (PsA).
Calprotectin or S100A8/S100A9 protein is recognized as a
damage-associated molecular pattern protein and indicates primarily neutrophil
activation. Matthias Jarlborg et al. examined whether the serum calprotectin is
associated with disease activity and severity in RA, axSpA, and PsA.
On the whole, 1729 patients were
included from the Swiss Clinical Quality Management (SCQM) registry. Out
of these, 969 were RA patients, 451 were axSpA
patients and 237 were PsA patients. And, 72 asymptomatic first-degree
relatives of patients with RA were regarded as healthy controls (HC). Their serum calprotectin was calculated.
Different outcomes were used for the 3 rheumatic diseases as:
The Kruskal-Wallis tests were used to compare the outcomes
by calprotectin quartile levels for continuous outcomes or trend tests for
categorical outcomes.
As found, in every disease
group, the median levels of serum calprotectin were higher than HC. All the
clinical outcomes were found to be statistically different amongst quartiles of
serum calprotectin, demonstrating a possible link between calprotectin levels
and higher disease activity (SJC, DAS, and USPD scores) and severity (joint
radiographs and HAQ). An association between the levels of calprotectin and
ASDAS score and occurrence of coxitis was revealed in axSpA. The SJC and DAPSA
did not vary across calprotectin quartiles for PsA patients.
Arthritis Research & Therapy
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
Matthias Jarlborg et al.
Comments (0)